Publications

Pembrolizumab (Pembro) for Recurrent Head and Neck Squamous Cell Carcinoma (Hnscc): Post Hoc Analyses of Phase 3 Keynote-040 Prior Radiation Treatment (Rt) and Disease State.

AuthID
P-00R-4A9

Author(s)

Harrington, KJ

Cohen, EEW

Soulieres, D

Dinis, J

Licitra, LF

Ahn, MJ

Soria, A

Machiels, JPH

Mach, N

Mehra, R

Burtness, B

Lin, JX

Cheng, JD

Swaby, RF

Le Tourneau, C

Document Type

Abstract

Year published

2019

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 37, Issue: 15

Conference

Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: MAY 31-JUN 04, 2019, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1200/jco.2019.37.15_suppl.6026

Wos: WOS:000487345805610

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Pembrolizumab (Pembro) for Recurrent Head and Neck Squamous Cell Carcinoma (Hnscc): Post Hoc Analyses of Phase 3 Keynote-040 Prior Radiation Treatment (Rt) and Disease State.

Useful Links

Get Help

Federated Authentication (Click on the image)

Pembrolizumab (Pembro) for Recurrent Head and Neck Squamous Cell Carcinoma (Hnscc): Post Hoc Analyses of Phase 3 Keynote-040 Prior Radiation Treatment (Rt) and Disease State.

Useful Links

Get Help